Sun Pharma gets USFDA nod for generic drug Mesalamine extended release capsules
New Delhi, May 12 Sun Pharmaceutical Industries on Thursday said it has received final approval from the US health regulator for Mesalamine extended release capsules, used to treat bowel disease, in the American market. The company has received approval from...
Updated At : 02:40 AM May 13, 2022 IST
Advertisement
New Delhi, May 12
Advertisement![]()
Sun Pharmaceutical Industries on Thursday said it has received final approval from the US health regulator for Mesalamine extended release capsules, used to treat bowel disease, in the American market.
The company has received approval from the US Food and Drug Administration (USFDA) for the product, a generic version of Pentasa extended release capsules (500 mg), the Mumbai-based drug major said in a statement.
Advertisement
As per March 2022 IQVIA Health data, Pentasa had annualised sales of around USD 213 million in the US market.
Advertisement
×
Unlock Exclusive Insights with The Tribune Premium
Take your experience further with Premium access.
Thought-provoking Opinions, Expert Analysis, In-depth Insights and other Member Only Benefits
Yearly
Monthly
Already a Member? Sign In Now
Advertisement
Advertisement
Advertisement
Copyright © The Tribune Trust, 2024
Designed and developed by : 
